BD Micro-Delivery System Licensed by Sanofi Pasteur; Technology has Potential to Improve Efficiency of Influenza Vaccine
FRANKLIN LAKES, N.J. -- BD (Becton, Dickinson and Company) has entered into an agreement with sanofi pasteur, the vaccines business of the sanofi-aventis Group, to license the BD Micro-Delivery System for use in the administration of sanofi pasteur's human vaccine products.
Most vaccines are delivered via intramuscular injection. This BD patented technology provides a new method of delivering vaccine into the upper layer of the skin. The results of early-phase clinical research have shown that this method of delivery has the potential to improve the immunogenicity and efficiency of the delivered vaccine.
"We are very pleased to enter into this collaboration with sanofi pasteur," said Gary Cohen, president of BD Medical. "We believe that our BD Micro-Delivery System has the potential to help address some of the important health challenges facing the world today, and embodies BD's company purpose of helping all people live healthy lives."
The BD Micro-Delivery System is designed to be pre-filled with vaccine and to easily and reliably deliver the vaccine to the skin. The system features a tiny "microneedle." Clinical testing indicates that the "microneedle" is barely perceptible when it enters the skin.
"In practical terms, the BD Micro-Delivery System has the potential to increase a patient's acceptance of vaccine as well and enable vaccination of more people with less vaccine," said Alexandre Conroy, president of BD Medical Pharmaceutical Systems.
Under the terms of the agreement, BD will provide sanofi pasteur with a license to the BD Micro-Delivery System in the field of human vaccines. The parties will continue to work together to demonstrate its applicability to delivering a wide variety of vaccines, including the influenza vaccine that is now being tested in human clinical trials conducted in conjunction with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID).
Per the agreement, BD will be compensated for use of the BD Micro-Delivery System provided to sanofi pasteur, which will develop, manufacture and commercialize the vaccine-filled BD Micro-Delivery Systems.
Source: sanofi pasteur, BD
Â
Â
Newsletter
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
